upndown1313

Big Pharma: Where's the Risk Management?

Sorry not impressed, either with oral-Lyn data that has been presented or the concept of a metformin chewing gum. Based on PhII results, PhIII will not get approval fro Oral-Lyn. Sorry, but this is a scam company at best. Not reckless, but a realist.


On Jul 07 06:51 PM Oil wrote:

> Generex has additional factors in it's favor. It's bioequivalent
> study has shown their "Metcontrol" chewing gum to be interchangeable
> with Metformin tablets. Article here; finance.yahoo.com/news...;.v=1
> Metformin according to research is the 2nd most prescribed drug for
> type 2 diabetes. Generex plans to begin applying for approval in
> first quarter 2010. Also the wholly owned subsidiary Antigen Express
> claims to currently have the technology to vastly out produce the
> traditional method of vaccine production. Article; www.telegram.com/artic...
>
>
> To upndown1313, This article does not compare Generex to Pfizer.
> The article simply suggests an opportunity for a big company to buy
> or license from Generex. And mentions the big company's failures
> in the insulin market. Also it's probably reckless to say Oral-Lyn
> will "never" get approval in a major market because the delivery
> method is highly variable and unreliable. If clinical trials are
> going well then it's hard (foolish?) to argue with results.

Big Pharma: Where's the Risk Management?

GNBT is about as highly speculative as you can get. Right up there with the likes of GNTA et al. Oral-Lyn will never get approval in a major martket. Absorption is highly variable and unreliable. I agree that Big Pharma is stumbling around in this environment, but comparing this joke of a company called Generex to PFE is absolutely ludicrous. This begs the question, where is your risk management or are you just clueless?

Downturn Has Transformed Drug Company Business Model

Write facts, but wrong interpretation. Big Pharma spending at CRO probably hasn't changed much, but rather the smaller, more virtual biotechs who have dramtically cut back on their spending due to the lack of funds and lack of access to credit markets due to the credit crunch.

Pfizer’s Celebrex: Mass Tort Madness

Merck's own brand of tort reform has slowed these "cock-a-roaches considerably" The 2 recent VIOXX appeals and overtuning of large awards will send Lanier and his gang , hopefully to do pro bono work for real people with real problems. Once can only hope.